Received: 5 June 2020
Accepted: 7 January 2021
First Online: 15 February 2021
: P.A.M.: Takeda, uncompensated speaking; Amgen, stock ownership; Ipsen, mock ODAC panel; Salarius, mock ODAC panel; P.A.M.’s spouse: Boehringer Ingelheim, consulting; Genentech, speakers’ bureau; Eastern Pulmonary Society. N.K.C. holds ownership interest/equity in Y-mAbs Therapeutics, Inc., reports receiving commercial research grants from Y-mAbs Therapeutics, Inc., and Abpro Labs, Inc., holding ownership interest/equity in Abpro Labs and owning stock options in Eureka Therapeutics, Inc. N.K.C. is a scientific advisory board member of Abpro Labs and Eureka Therapeutics. N.K.C. is the inventor and owner of issued patents licensed by MSK to Y-mAbs Therapeutics, Biotec Pharmacon and Abpro Labs. I.J.D. has done consulting and advisory board activities with Apexigen, AstraZeneca, Bayer, Bristol-Myers Squibb/Celgene, Fennec and Roche. I.J.D. has served as an institutional PI for pharma-sponsored clinical trials at MSKCC from Bristol-Myers Squibb, Genentech and Novartis. M.K. has consultant agreements with AstraZeneca, Bayer, CereXis, QED Therapeutics and Recursion Pharma (personal fees received). S. Modak. is a consultant to Y-mAbs Therapeutics, Inc., Illumina, Inc., and Progenics Pharmaceuticals. Z.K.S.’s immediate family member serves as a consultant for Allergan, Adverum Biotechnologies, Alimera Sciences, Fortress Biotech, Genentech/Roche, Novartis, Optos, Regeneron, Regenxbio and Spark Therapeutics.
Free to read: This content has been made available to all.